We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-6.91%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$488M
AUM Growth
-$65.2M
Cap. Flow
-$17.8M
Cap. Flow %
-3.65%
Top 10 Hldgs %
32.78%
Holding
126
New
4
Increased
19
Reduced
35
Closed
4

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$5.8M
2
INCY icon
Incyte
INCY
+$5.8M
3
BCR
CR Bard Inc.
BCR
+$5.67M
4
AKRX
Akorn Inc
AKRX
+$4.79M
5
EW icon
Edwards Lifesciences
EW
+$3.89M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$6.82M
2
ILMN icon
Illumina
ILMN
+$5.64M
3
AMSG
Amsurg Corp
AMSG
+$4.79M
4
SYK icon
Stryker
SYK
+$2.92M
5
CI icon
Cigna
CI
+$2.88M

Sector Composition

Rank Sector Weight
1 Healthcare 91.87%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGENF
51
DELISTED
QIAGEN NV
QGENF
$2.56M 0.53%
91,500
– –
DXCM icon
52
DexCom
DXCM
$29.6B
$2.45M 0.5%
+164,000
New +$2.91M
PRGO icon
53
Perrigo
PRGO
$1.48B
$2.41M 0.49%
29,000
-13,700
-32% -$1.19M
ALKS icon
54
Alkermes
ALKS
$8.79B
$2.36M 0.48%
42,500
-9,000
-17% -$481K
NUVA
55
DELISTED
NuVasive, Inc.
NUVA
$2.36M 0.48%
35,000
-25,000
-42% -$1.61M
CYTO
56
DELISTED
Altamira Therapeutics Ltd
CYTO
$2.32M 0.48%
27
– –
NKTR icon
57
Nektar Therapeutics
NKTR
$2.31B
$2.28M 0.47%
12,400
– –
SGEN
58
DELISTED
Seagen Inc. Common Stock
SGEN
$2.27M 0.46%
43,000
– –
TMO icon
59
Thermo Fisher Scientific
TMO
$198B
$2.26M 0.46%
16,000
– –
GMED icon
60
Globus Medical
GMED
$10.5B
$2.18M 0.45%
87,700
– –
ENDP
61
DELISTED
Endo International plc
ENDP
$2.04M 0.42%
124,000
-66,000
-35% -$1.16M
AET
62
DELISTED
Aetna Inc
AET
$2.03M 0.42%
16,400
– –
MASI
63
DELISTED
Masimo
MASI
$2.02M 0.41%
30,000
-40,000
-57% -$2.46M
PRTA icon
64
Prothena Corp
PRTA
$453M
$2.02M 0.41%
41,000
– –
AGIO icon
65
Agios Pharmaceuticals
AGIO
$2.36B
$1.88M 0.38%
45,000
– –
ALR
66
DELISTED
Alere Inc
ALR
$1.87M 0.38%
47,983
+17,983
+60% +$728K
BLUE
67
DELISTED
bluebird bio
BLUE
$1.79M 0.37%
2,239
– –
HCA icon
68
HCA Healthcare
HCA
$82.3B
$1.76M 0.36%
23,800
-7,400
-24% -$554K
ANGO icon
69
AngioDynamics
ANGO
$558M
$1.72M 0.35%
101,700
-28,300
-22% -$472K
MGNX icon
70
MacroGenics
MGNX
$285M
$1.7M 0.35%
83,000
– –
NVDQ
71
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.63M 0.33%
230,000
– –
PFE icon
72
Pfizer
PFE
$143B
$1.62M 0.33%
52,700
– –
MRK icon
73
Merck
MRK
$315B
$1.62M 0.33%
28,820
-20,436
-41% -$1.2M
XENT
74
DELISTED
Intersect ENT, Inc
XENT
$1.57M 0.32%
130,000
-75,325
-37% -$975K
RDUS
75
DELISTED
Radius Health, Inc.
RDUS
$1.52M 0.31%
40,000
-21,000
-34% -$999K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2016 Portfolio in Review

As of Q4 2016, Bellevue Group held 126 positions worth $488M, down 12% from $553M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group withdrew a net $17.8M in Q4 2016, closing 4 positions and reducing 35 holdings. Its most notable exit was Amsurg Corp, an estimated $4.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Danaher worth $5.76M.

  • Bellevue Group's largest Q4 2016 buy was Danaher: 83,472 shares worth $5.76M.
  • Bellevue Group added most to Incyte in Q4 2016, an estimated $5.8M increase.
  • Bellevue Group's biggest Q4 2016 reduction was Cardinal Health, cutting an estimated $6.82M.
  • Bellevue Group fully exited Amsurg Corp in Q4 2016, selling an estimated $4.79M.
  • Bellevue Group's ten largest holdings make up 33% of its $488M portfolio in Q4 2016.
  • Bellevue Group opened 4 new positions and closed 4 in Q4 2016.
  • Bellevue Group's portfolio value fell 12% quarter-over-quarter to $488M.

Based on Bellevue Group's 13F filing for Q4 2016, filed 10 Feb 2017.